Cargando…
LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma
BACKGROUND & AIMS: Gemcitabine resistance is rapidly acquired by pancreatic ductal adenocarcinoma (PDAC) patients. Novel approaches that predict the gemcitabine response of patients and enhance gemcitabine chemosensitivity are important to improve patient survival. We aimed to identify genes as...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505810/ https://www.ncbi.nlm.nih.gov/pubmed/32615164 http://dx.doi.org/10.1016/j.jcmgh.2020.06.009 |
_version_ | 1783584893315317760 |
---|---|
author | Zhu, Yin-Xin Li, Chi Han Li, Guolin Feng, Huiyi Xia, Tian Wong, Chi Hin Fung, Frederic Khe Cheong Tong, Joanna Hung-Man To, Ka-Fai Chen, Rufu Chen, Yangchao |
author_facet | Zhu, Yin-Xin Li, Chi Han Li, Guolin Feng, Huiyi Xia, Tian Wong, Chi Hin Fung, Frederic Khe Cheong Tong, Joanna Hung-Man To, Ka-Fai Chen, Rufu Chen, Yangchao |
author_sort | Zhu, Yin-Xin |
collection | PubMed |
description | BACKGROUND & AIMS: Gemcitabine resistance is rapidly acquired by pancreatic ductal adenocarcinoma (PDAC) patients. Novel approaches that predict the gemcitabine response of patients and enhance gemcitabine chemosensitivity are important to improve patient survival. We aimed to identify genes as novel biomarkers to predict the gemcitabine response and the therapeutic targets to attenuate chemoresistance in PDAC cells. METHODS: Genome-wide RNA interference screening was conducted to identify genes that regulated gemcitabine chemoresistance. A cell proliferation assay and a tumor formation assay were conducted to study the role of lethal giant larvae homolog 1 (LLGL1) in gemcitabine chemoresistance. Levels of LLGL1 and its regulating targets were measured by immunohistochemical staining in tumor tissues obtained from patients who received gemcitabine as a single therapeutic agent. A gene-expression microarray was conducted to identify the targets regulated by LLGL1. RESULTS: Silencing of LLGL1 markedly reduced the gemcitabine chemosensitivity in PDAC cells. Patients had significantly shorter survival (6 months) if they bore tumors expressing low LLGL1 level than tumors with high LLGL1 level (20 months) (hazard ratio, 0.1567; 95% CI, 0.05966–0.4117). Loss of LLGL1 promoted cytokine receptor oncostatin M receptor (OSMR) expression in PDAC cells that led to gemcitabine resistance, while knockdown of OSMR effectively rescued the chemoresistance phenotype. The LLGL1-OSMR regulatory pathway showed great clinical importance because low LLGL1 and high OSMR expressions were observed frequently in PDAC tissues. Silencing of LLGL1 induced phosphorylation of extracellular signal-regulated kinase 2 and specificity protein 1 (Sp1), promoted Sp1 (pThr453) binding at the OSMR promoter, and enhanced OSMR transcription. CONCLUSIONS: LLGL1 possessed a tumor-suppressor role as an inhibitor of chemoresistance by regulating OSMR–extracellular signal-regulated kinase 2/Sp1 signaling. The data sets generated and analyzed during the current study are available in the Gene Expression Omnibus repository (ID: GSE64681). |
format | Online Article Text |
id | pubmed-7505810 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-75058102020-09-28 LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma Zhu, Yin-Xin Li, Chi Han Li, Guolin Feng, Huiyi Xia, Tian Wong, Chi Hin Fung, Frederic Khe Cheong Tong, Joanna Hung-Man To, Ka-Fai Chen, Rufu Chen, Yangchao Cell Mol Gastroenterol Hepatol Original Research BACKGROUND & AIMS: Gemcitabine resistance is rapidly acquired by pancreatic ductal adenocarcinoma (PDAC) patients. Novel approaches that predict the gemcitabine response of patients and enhance gemcitabine chemosensitivity are important to improve patient survival. We aimed to identify genes as novel biomarkers to predict the gemcitabine response and the therapeutic targets to attenuate chemoresistance in PDAC cells. METHODS: Genome-wide RNA interference screening was conducted to identify genes that regulated gemcitabine chemoresistance. A cell proliferation assay and a tumor formation assay were conducted to study the role of lethal giant larvae homolog 1 (LLGL1) in gemcitabine chemoresistance. Levels of LLGL1 and its regulating targets were measured by immunohistochemical staining in tumor tissues obtained from patients who received gemcitabine as a single therapeutic agent. A gene-expression microarray was conducted to identify the targets regulated by LLGL1. RESULTS: Silencing of LLGL1 markedly reduced the gemcitabine chemosensitivity in PDAC cells. Patients had significantly shorter survival (6 months) if they bore tumors expressing low LLGL1 level than tumors with high LLGL1 level (20 months) (hazard ratio, 0.1567; 95% CI, 0.05966–0.4117). Loss of LLGL1 promoted cytokine receptor oncostatin M receptor (OSMR) expression in PDAC cells that led to gemcitabine resistance, while knockdown of OSMR effectively rescued the chemoresistance phenotype. The LLGL1-OSMR regulatory pathway showed great clinical importance because low LLGL1 and high OSMR expressions were observed frequently in PDAC tissues. Silencing of LLGL1 induced phosphorylation of extracellular signal-regulated kinase 2 and specificity protein 1 (Sp1), promoted Sp1 (pThr453) binding at the OSMR promoter, and enhanced OSMR transcription. CONCLUSIONS: LLGL1 possessed a tumor-suppressor role as an inhibitor of chemoresistance by regulating OSMR–extracellular signal-regulated kinase 2/Sp1 signaling. The data sets generated and analyzed during the current study are available in the Gene Expression Omnibus repository (ID: GSE64681). Elsevier 2020-06-29 /pmc/articles/PMC7505810/ /pubmed/32615164 http://dx.doi.org/10.1016/j.jcmgh.2020.06.009 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Zhu, Yin-Xin Li, Chi Han Li, Guolin Feng, Huiyi Xia, Tian Wong, Chi Hin Fung, Frederic Khe Cheong Tong, Joanna Hung-Man To, Ka-Fai Chen, Rufu Chen, Yangchao LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma |
title | LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma |
title_full | LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma |
title_fullStr | LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma |
title_full_unstemmed | LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma |
title_short | LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma |
title_sort | llgl1 regulates gemcitabine resistance by modulating the erk-sp1-osmr pathway in pancreatic ductal adenocarcinoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505810/ https://www.ncbi.nlm.nih.gov/pubmed/32615164 http://dx.doi.org/10.1016/j.jcmgh.2020.06.009 |
work_keys_str_mv | AT zhuyinxin llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma AT lichihan llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma AT liguolin llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma AT fenghuiyi llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma AT xiatian llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma AT wongchihin llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma AT fungfrederickhecheong llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma AT tongjoannahungman llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma AT tokafai llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma AT chenrufu llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma AT chenyangchao llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma |